- Policy
- Combination indication for Entresto has changed
- by Lee, Hye-Kyung Feb 24, 2022 05:58am
- The range of patients who can use Entresto (Sacubitril/Valsartan), a treatment for chronic heart failure of Novartis Korea, has become a little clearer. Until now, there has been a debate over the normal range of left ventricular ejection rates, with "chronic heart failure patients with decreased left ventricular contraction function." On Feb
- Company
- It was improved by changing the targeted therapy formulation
- by Eo, Yun-Ho Feb 23, 2022 05:50am
- According to related industries, Pfizer Korea's breast cancer treatment Ibrance(Palbociclib) has obtained an item license in a type of tablet not a capsule, six years after its launch in Korea. Also, Takeda is also preparing to introduce a tablet formulation of "Zejula (Niraparib toosylate monohydrate)," a treatment for ovarian cancer.
- Policy
- Competition in full swing for the ₩100 bil Humira mkt
- by Lee, Tak-Sun Feb 23, 2022 05:50am
- Competition in the domestic Humira biosimilar market is expected to unfold with Celltrion's entry into the market. On how the market that was once dominated by its only biosimilar option, Samsung Bioepis’ Adalloce, will change with the entry of Celltrion in the market, remains the focus of attention. Humira, which is mainly used to treat
- Company
- Lilly-RosVivo signed a contract to transfer diabetes txs
- by Eo, Yun-Ho Feb 23, 2022 05:49am
- Nexturn Bio announced on the 22nd that its U.S. subsidiary RosVivo Therapheutics has signed a "MTA (Material Transfer Agreement)" with Eli Lilly for commercial development of a new drug candidate for diabetes treatment, "RSVI-301. MTA is a contract concluded by the counterparty to verify the efficacy and research results of the drug through e
- Policy
- Jae-Myung Lee pledges to enact Special Bio Act
- by Lee, Jeong-Hwan Feb 23, 2022 05:49am
- Presidential candidate Jae-Myung Lee of the Democratic Party of Korea announced that he will prepare an appropriate compensation system for domestically developed drugs and new drugs that conduct clinical trials in Korea and enact a ‘Special Act on the Development of the Biohealth Industry’ to foster and develop the Korean bio-health indus
- Opinion
- [Reporter's view]Will it be different this time?
- by Kim, Jin-Gu Feb 23, 2022 05:49am
- Earlier this month, the government announced "Comprehensive Measures for Stable Supply of National Essential Drugs." In the wake of the COVID-19 crisis, the importance of stockpiling and supplying essential medicines has increased, and the government has stepped up. National essential drugs refer to drugs that are essential for health care
- Policy
- Galvus generics to be reimbursed despite exclusivity period
- by Lee, Tak-Sun Feb 22, 2022 05:55am
- Generic versions of the anti-diabetic DPP-4 inhibitor ‘Galvus (vildagliptin)’ will be released on the 5th of next month in the marketing exclusivity period that is approved for first generics. This is due to the substance patent period of Galvus that will expire the day before. Therefore, Ahn-gook Pharmaceuticals’ marketing exclusivit
- InterView
- Sanofi introduces digital solutions for customers & patients
- by Eo, Yun-Ho Feb 22, 2022 05:55am
- The recent management trend of global big perm is choice and concentration. The number of companies strengthening and separating specialized areas through mergers and spraying has increased significantly. Sanofi Group, a French pharmaceutical company, was originally specialized in diabetes drugs such as insulin, but it absorbed Genzyme, a
- Policy
- Keytruda to be reimbursed as first-line treatment for NSCLC
- by Lee, Tak-Sun Feb 22, 2022 05:54am
- A new category will be added to reimburse MSD’s NSCLC treatment ‘Keytruda’ as a first-line treatment. This is the first anticancer immunotherapy released in Korea to be reimbursed for NSCLC, five years into its approval as a first-line treatment for non-small-cell lung cancer in Korea. The drug passed deliberations by the Health Insur
- Company
- Endless evolution of cancer immunotherapy
- by Eo, Yun-Ho Feb 22, 2022 05:54am
- According to related industries, news of approval for the expansion of domestic indications of cancer immunotherapy Opdivo (Nivolumab) and Keytruda (Pembrolizumab) in PD-1 inhibition mechanisms continues. Although it is the same mechanism, it is competing by securing different indications. In the case of Opdivo, two postoperative adjuvant the
